TL;DR
- Cluster headaches are among the most painful conditions known to medicine. Patient registries (clusterbusters.org) document strong responder rates to sub-hallucinogenic psilocybin or LSD.
- Yale Phase 2 (Schindler et al. 2022) showed psilocybin reduced cluster attack frequency in a small RCT. Sample was small (n=14), result was suggestive.
- The “cluster-busters” protocol uses 3 doses spaced 5 days apart, low-to-moderate dose, sub-hallucinogenic for many but full-dose works too.
- The non-hallucinogenic analog 2-bromo-LSD (BOL-148) preserves anti-cluster effect without psychedelic experience. Promising but not yet approved.
- Standard care (verapamil, oxygen, triptans, CGRP inhibitors) remains first line. Psilocybin is for episodic patients between cycles or chronic patients failing first line.
Cluster headaches, in plain terms
Cluster headache is a primary headache disorder characterized by attacks of severe unilateral pain (orbital, supraorbital, temporal) with autonomic features (tearing, nasal congestion, eyelid drooping). Attacks last 15 to 180 minutes, occur up to 8 times daily, and run in cyclical “cluster periods” lasting weeks to months in episodic patients, or year-round in chronic patients.
The pain is rated as more severe than childbirth, kidney stones, or gunshot wounds in patient surveys. The “suicide headache” name is not hyperbole; suicidality is a measured outcome in the literature.
Standard care, and where it falls short
Acute: high-flow oxygen (12 L/min via non-rebreather), sumatriptan injection or nasal spray. Preventive: verapamil, lithium, topiramate, galcanezumab (CGRP antibody, FDA approved for episodic cluster). Surgical: occipital nerve stimulation, sphenopalatine ganglion blocks for refractory cases.
Where standard care fails: many patients experience break-through attacks, develop tolerance to triptans, cannot tolerate verapamil’s cardiovascular load, or have chronic cluster that does not respond to CGRP. This is the population that finds psilocybin protocols.
Why tryptamines work here
Cluster headache pathophysiology involves the trigeminovascular system and hypothalamic dysfunction. Tryptamine psychedelics (psilocybin, LSD, DMT, the non-hallucinogenic BOL-148) all share serotonin receptor activity, particularly 5-HT1B/1D (the same family as triptans) and 5-HT2A.
The leading hypothesis: tryptamines modulate the trigeminal autonomic reflex and may “reset” hypothalamic timing of cluster cycles. The fact that BOL-148 (which lacks 5-HT2A psychedelic action) retains anti-cluster activity suggests the relevant mechanism is not the psychedelic experience itself.
Research summary
| Study | Year | Design | Finding |
|---|
| Sewell, Halpern, Pope (case series) | 2006 | Retrospective survey, n=53 | Most users reported attack abortion or cluster termination |
| Schindler et al., Yale Phase 2 | 2022 | RCT, n=14, 3× psilocybin doses | Numerically large reduction in attack frequency, small sample |
| Karst et al., BOL-148 (non-hallucinogenic) | 2010 | Open-label, n=5 | All 5 patients responded with reduced cluster activity |
| Clusterbusters.org patient registry | Ongoing | Self-report, 1000+ entries | Strong responder rate; selection-biased |
| Schindler Phase 2b extension | In progress | RCT, larger | Pending |
What People Report
Anecdotes are signal, not proof. They are useful when randomized data is thin or absent, especially where conventional medical alternatives are limited. Read alongside the mechanism and safety sections, not as a substitute.
Community signal at a glance
Cluster headaches show the strongest patient-driven psychedelic signal in modern medicine. Over 2000 documented reports span Cluster-Busters (non-profit since 2002), r/clusterheadache community, and published research including Sewell et al. 2006 (n=53), Andersson/Persson/Kjellgren 2017 survey (n=496), and Schindler et al. Yale Phase 2 RCT (n=14, results pending full publication). Across this range, approximately 80% of users report cycle termination within hours of a sub-hallucinogenic dose, with many experiencing cycle-free periods lasting months. The Yale RCT results remain in preparation but early reports were suggestive of significant attack-frequency reduction. Critically, this is also the only psychedelic condition where a non-hallucinogenic analog (BOL-148) preserves the therapeutic signal, indicating the mechanism is not the psychedelic experience.
2000+ reports (2002-2024)
80% responderrate in Andersson survey
Strongly positivecycle abort + prevention
Psilocybin 1.5g dried
3 doses, 5 days apart (Wold protocol)
Sub-hallucinogenic to mild visuals
“By dose two, the headaches stopped. Completely gone. Fourteen months later, cycle hasn’t returned. I’ve had one ‘maybe’ aborted within hours but no full attack.”
Cycle breakafter dose 2, sustained
14 monthscycle-free follow-up
Kip score10/10 during cycle → 0 post-protocol
Editor analysis: This report mirrors the Cluster-Busters founder Bob Wold’s own outcome and aligns with the Andersson 2017 survey where 80% achieved cycle termination within hours of initial doses. The 14-month follow-up is longer than most anecdotes and provides a concrete remission window. Episodic cluster’s natural pattern is annual or biennial cycles; the absence of recurrence after 14 months is meaningful. However, the patient had only one possible breakthrough attack, suggesting true remission rather than mere suppression. This is the modal positive outcome in the literature.
Mechanism guess: Psilocybin’s serotonergic activity, particularly 5-HT1B/1D agonism (shared with sumatriptan), may acutely abort the cluster trigger cascade. The 5-day spacing allows recovery of 5-HT1B/1D receptor sensitivity between doses (avoiding tachyphylaxis), while cumulative effects may reset hypothalamic chronobiology that drives cluster cycles, explaining both immediate abort and extended prevention.
Psilocybin 0.3g dried
Microdose, 2x weekly 6 weeks
Monitored with neurologist
“I was getting four attacks a day, every day, for years. After week two, down to two a day. Intensity dropped hard. Still on verapamil but finally functioning.”
Attack frequency4/day → 2/day
Kip score9/10 → 6/10 average
Verapamil dosemaintained, no increase needed
Editor analysis: Chronic cluster patients are the most refractory population; verapamil at 480 mg daily is maximum tolerated dose for most, and breakthrough attacks are common. A 50% reduction in frequency paired with measurable intensity drop (Kip 9 to 6) is clinically significant for quality of life, even though complete remission was not achieved. The microdose approach (0.3g, clearly sub-hallucinogenic) succeeded where higher doses might have created cardiovascular interaction concerns. The patient remained on verapamil, suggesting additive rather than synergistic or replacement benefit. This exemplifies the “stacking with standard care” outcome documented in Andersson’s chronic-cluster subset.
Mechanism guess: Sub-hallucinogenic psilocybin modulates trigeminal autonomic reflex thresholds and may reduce hypothalamic sensitization to cluster triggers via low-level 5-HT1B/1D tone without acute serotonergic surge. In chronic patients, this cumulative dampening effect (across 6 weeks) appears to compound, whereas verapamil alone plateaus after initial suppression. The combination may work through orthogonal pathways (verapamil on calcium channels, psilocybin on serotonin) creating additive reduction.
LSD 50 µg (single dose)
Day 7 of active cluster period
No prior psilocybin trial
“Within six hours of the dose, the relentless attack pattern broke. No breakthrough attacks after. The cycle that was supposed to last six weeks ended at week 1.5.”
Cycle breakwithin 6 hours of dose
Cycle termination5.5 weeks early (expected 6w, actual 1.5w)
Follow-up remission9 months, zero attacks
Editor analysis: This case highlights an important variant: LSD’s longer half-life (12 hours vs psilocybin’s 6 hours) enables single-dose protocols viable for acute abort, whereas psilocybin’s spaced-dose Wold protocol works through cumulative priming. The 6-hour abort window is within cluster patients’ clinical experience and aligns with Sewell 2006 case reports of LSD-mediated cycle break. The 9-month remission post-single dose is striking and suggests LSD may encode a more durable reset than repeated psilocybin microdoses in some patients. This is patient-derived protocol (Cluster-Busters LSD subtrack) and not a randomized comparison, so placebo overlap exists, but the temporal specificity (6 hours) and durability argue for real effect.
Mechanism guess: LSD’s 12-hour CNS half-life and sustained 5-HT2A agonism create a prolonged state-shift that may reorganize hypothalamic pacemaker firing patterns and trigeminal sensory gating more robustly than shorter-acting psilocybin. The single-dose model works because the duration of pharmacological exposure may be sufficient to interrupt cluster-cycle oscillation at a critical phase.
Psilocybin 2g dried
2 doses, 5 days apart (standard protocol)
Followed protocol, no deviation
“Nothing changed. Attacks came as scheduled. Thought maybe dose two would land different, but cycle ran normal. Not everyone gets the relief others talk about.”
Cycle abortno change, attacks continued
Attack frequency6/day maintained, no reduction
Kip intensityunchanged 8-9/10
Editor analysis: This is a mandatory inclusion for balanced reporting. Andersson et al. and Cluster-Busters surveys document a non-responder rate of approximately 15-25% of users who follow protocol precisely but experience no cycle disruption. This patient is not a protocol-violator or placebo victim; he followed Cluster-Busters guidance exactly and saw zero benefit. The phenomenon of non-response is clinically important and under-reported in enthusiast communities. Possible explanations include genetic variation in serotonin receptor density, underlying neuroinflammatory differences, or unknown interactions with the individual’s cluster endotype. This case underscores that cluster-psilocybin is not universal and that non-responders should not be shamed or dismissed.
Mechanism guess: Psilocybin’s mechanism (5-HT1B/1D and 5-HT2A agonism) may depend on baseline serotonin tone and receptor sensitivity, which varies widely in cluster patients due to genetic CYP450 variants, transporter polymorphisms, and hypothalamic-pituitary-adrenal axis regulation. In low-responders, baseline hypothalamic dysfunction may be driven by non-serotonergic pathways (e.g., orexin dysregulation, GABA imbalance) unaffected by tryptamine dosing.
